Return to content in this issue

 

Benralizumab: Resolution of Eosinophilic Pulmonary Vasculitis in a Patient With EGPA

Bormioli S1, Vultaggio A2, Nencini F2, Comin CE3, Bercich L4, Bezzi M5, Vivarelli E2, Calosi L6, Chiccoli F1, Matucci A2

1Immunology and Cellular Therapy, AOU Careggi, University of Florence, Florence, Italy
2Immunoallergology Unit, AOU Careggi, University of Florence, Florence, Italy
3Department of Experimental and Clinical Medicine Section of Surgery, Histopathology and Molecular Pathology, University of Florence, Florence, Italy
4Department of Pathology, ASST Spedali Civili of Brescia, Brescia, Italy
5UOC Pneumology Endoscopic Unit, ASST Spedali Civili of Brescia, Brescia, Italy
6Department of Experimental & Clinical Medicine, Section of Anatomy & Histology & Research Unit of Histology & Embryology, University of Florence, Florence, Italy

J Investig Allergol Clin Immunol 2021; Vol 31(6) : 519-521
doi: 10.18176/jiaci.0689

Key words: Asthma, Eosinophilic vasculitis, Bronchial alveolar lavage, Benralizumab, EGPA